RxDoctor Payments Data

David Lans, DO

Rheumatology · New Rochelle, NYNPI 1720086051

Payments from drug & device makers

$15,312in general payments, 2019–2025

Across 845 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Pfizer$979
  • UCB, Inc.$808
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$14,76796%
  • Education$5454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,312 in reported general payments places this provider in the 70th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$1,267,387
Medicare patients
234
Services billed
115,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xeljanz XrTofacitinib Citrate36$244,935
RinvoqUpadacitinib22$225,983
Humira(Cf) PenAdalimumab21$145,639
OtezlaApremilast25$115,097
Cimzia (2 Pack)Certolizumab Pegol18$95,671
RemicadeInfliximab13$89,212
FarxigaDapagliflozin Propanediol11$15,429
MounjaroTirzepatide12$12,692
EliquisApixaban21$10,853
Xtampza ErOxycodone Myristate11$8,429
FioricetButalb/Acetaminophen/Caffeine14$5,912
MethotrexateMethotrexate Sodium82$3,734
Diclofenac Sodium14$3,554
Hydroxychloroquine Sulfate52$2,340
Duloxetine Hcl44$2,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Synthroid$2,118$227,32233 claims
AmgenOtezla$2,662$115,09725 claims
UCB, Inc.Cimzia (2 Pack)$808$95,67118 claims
Johnson & JohnsonRemicade$1,242$89,21213 claims
AstraZenecaFarxiga$2,427$15,42911 claims
Lilly USA, LLCMounjaro$584$12,69212 claims
PfizerEliquis$979$10,85321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 541 rheumatology providers in New York.

Other rheumatology in New Rochelle

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →